STAT+: What to watch on Akero's MASH-cirrhosis study results next month

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I’m suffering from post-JPM Week malaise. Not sick, thankfully, just the mental hangover that follows all that San Francisco nuttiness. 

What to watch for when Akero reports MASH-cirrhosis study results next month

In February, Akero Therapeutics will be reporting results from a nearly two-year, placebo-controlled study of its drug efruxifermin in patients with cirrhosis caused by the fatty liver disease known as MASH.

Continue to STAT+ to read the full story…